Introduction
============

Complex natural products, such as polyketides, have a well‐documented range of medicinal values ([@b9]). The therapeutic value associated with natural products has then placed an emphasis on finding methods to isolate and over‐produce such compounds, a task made difficult, in many cases, by the fastidious nature of the native microbial hosts responsible for the bulk of natural compounds. The challenges in producing therapeutic natural compounds from their original host organisms spurred the field of heterologous natural product biosynthesis where a natural product genetic sequence is transferred from the original producer to a new host system with capabilities that include improved growth speed, genetic and metabolic engineering potential, and improved prospects for process scale‐up and development ([@b12]).

Heterologous hosts include well‐characterized microbial organisms such as *Escherichia coli*, *Bacillus subtilis* and *Saccharomyces cerevisiae*. Each has been used in the context of heterologous complex natural product biosynthesis, and in each case, the genetic or molecular biology tools associated with the surrogate host greatly aided the heterologous transfer of the natural product pathways ([@b1]; [@b7]; [@b5]). In addition, the basic growth requirements and rapid growth speeds of the cited heterologous hosts further simplify efforts to reconstitute foreign natural product pathways. In this setting, production at even the lowest product titres signifies success of the heterologous metabolic engineering effort. Once a natural product pathway has been established, even more tools are then available to probe and further improve heterologous production with two ultimate goals: (i) to maximize production of a specific natural product and (ii) to better characterize and understand the interaction between native and heterologous metabolism such that the resulting information will facilitate future metabolic engineering efforts.

To provide an example relevant to the study conducted here, the complex polyketide compound 6‐deoxyerythronolide B (6dEB, the macrocyclic core of the antibiotic erythromycin) was produced through *E. coli* by engineering intracellular pathways for substrate provision and polyketide biosynthesis ([@b7]). The native *E. coli* operon for propionate catabolism was interrupted such that the only gene remaining was *prpE* (encoding a propionyl‐CoA synthetase). In addition, a non‐native propionyl‐CoA carboxylase (PCC, originally from *Streptomyces coelicolor*) was introduced to provide a metabolic pathway capable of converting exogenously fed propionate to propionyl‐CoA and (2S)‐methylmalonyl‐CoA, the two substrates needed by the three deoxyerythronolide B synthase (DEBS) biosynthetic enzymes responsible for 6dEB biosynthesis. However, prior to catalysing 6dEB formation, the DEBS enzymes require a posttranslational modification step catalysed by a phosphopantetheinyl transferase. Native to *B. subtilis*, a phosphopantetheinyl transferase gene termed *sfp* was transferred to the *E. coli* chromosome in the same step used to disrupt the *prp* operon.

Although the cellular design described for *E. coli*‐derived 6dEB resulted in positive production from the new host (with initial titres between 5 and 30 mg l^--1^), a simple mass balance confirmed that final 6dEB conversion fell well below 100%, typically only reaching 5--15% conversion ([@b6]; [@b3]). Thus, efforts have begun to analyse the cellular level biosynthetic process with goals that include identifying bottlenecks to production, improving current % conversion levels, and, more generally, offering a better understanding of the heterologous biosynthetic process. In this work, the heterologous components needed to facilitate *E. coli*‐derived 6dEB biosynthesis were studied in the context of gene expression variation. Gene copy levels of the heterologous components \[Sfp (posttranslational modification), DEBS (6dEB biosynthesis) and PCC (substrate provision)\] needed for 6dEB biosynthesis were varied to assess the resulting impact on final 6dEB production. Information gained could then be used to understand the relative impact of heterologous metabolism on 6dEB biosynthesis and as a basis for future efforts to improve the biosynthetic process.

Results and discussion
======================

The DEBS, PCC and Sfp enzymes are all heterologous with respect to native *E. coli* metabolism and are all required for eventual 6dEB biosynthesis ([@b7]). However, though it is known that each enzyme aids 6dEB biosynthesis, the relative impact of each is unknown. Moreover, future efforts to improve heterologous 6dEB biosynthesis will depend on identifying components that most influence and/or present bottlenecks to production. Therefore, we varied the levels of these important heterologous enzymes with the goal of determining which had the most impact on 6dEB biosynthesis. The experimental approach to do so involved altering the gene copy number associated with Sfp (posttranslational modification), DEBS (6dEB biosynthesis) and PCC (substrate provision) ([Table 1](#t1){ref-type="table"}). For DEBS, strain YW9, which contains the DEBS genes in the chromosome of *E. coli*, is compared with BAP1(pBP130/pBP144), which has the DEBS genes within medium copy pET plasmids. Similar strains were used to test the effects of Sfp and PCC on 6dEB biosynthesis ([Table 2](#t2){ref-type="table"}). In this manner, final titre levels (mg l^--1^ of 6dEB) would be correlated to gene dosage and expression of the necessary heterologous enzymes needed for 6dEB biosynthesis.

###### 

Strains and plasmids.

                     Description                                                                                                                                      Reference
  ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ ------------
  *E. coli* strain                                                                                                                                                    
   BAP1              F‐ ompT hsdS~B~ (r~B~‐m~B~‐) gal dcm (DE3) *prp*RBCD::T7prom‐*sfp*,T7prom‐*prpE*                                                                 [@b7])
   YW9               BAP1 *ygfG*::T7prom‐*accA1‐pccB*‐Kan^r^‐T7term, *araA*::T7 prom‐*DEBS1*‐T7term, *araB*::T7 prom‐*DEBS2*‐T7term, *araD*::T7 prom‐*DEBS3*‐T7term   [@b11])
   YW1               BAP1 *prpR*\<\>T7prom‐*accA1*‐rbs‐*pccB*‐T7term                                                                                                  This study
  Plasmid                                                                                                                                                             
   pBP130            pET21c (Carb^r^) derivative, T7prom‐*DEBS2*‐*DEBS3*‐T7term                                                                                       [@b7])
   pBP144            pET28 (Kan^r^) derivative, T7prom‐*pccB*‐rbs‐*accA1*‐T7prom‐*DEBS1*‐T7term                                                                       [@b7])
   pYW1200           pET21c derivative, T7prom‐*pccB*‐rbs‐*accA1*‐T7term                                                                                              This study
   pYW7317           pET28 derivative, T7prom‐*DEBS1*‐T7term                                                                                                          This study
   pACYC‐*sfp*       pACYCDuet‐1 (Cm^r^) derivative, T7prom‐*sfp*‐T7term                                                                                              This study

T7 promoters and terminators have been abbreviated as T7prom and T7term, respectively. T7 promoter regions also include a *lac* operator and a ribosomal binding sequence (rbs). Restriction enzymes and Phusion High‐Fidelity PCR Master Mix were purchased from New England Biolabs; PCR primers were synthesized by Operon. Restriction enzyme digestions, plasmid transformations, SDS‐PAGE and other standard molecular biology techniques were carried out as described by [@b8]). Plasmids pBP130 and pBP144 were constructed as described previously ([@b7]). Plasmid pYW7317 was constructed by digesting pBP144 with NdeI, which liberated the PCC genes, followed by vector self‐ligation. The *B. subtilis sfp* gene was isolated from pBP80 (a plasmid containing *sfp*, B. A. Pfeifer and C. Khosla, unpublished) as an NdeI/XhoI fragment and inserted into pACYCDuet‐1 (Novagen), resulting in pACYC‐*sfp*.

*Escherichia coli* strains BAP1 and YW9 have been described in previous work ([@b7]; [@b11]). To construct YW1, the method described by [@b2]) was used for chromosomal gene replacement. The PCC genes were first cloned from pBP144 into pET21c (pYW1200). The expression cassette containing the PCC subunit genes (T7prom‐*accA1*‐rbs‐*pccB*‐T7term) was then amplified by PCR with the following primers: 5′GTGCGCACCGGCGTGTACAATGCATCCTAGGAGATCTCGATCCC (forward) and 5′GCGTGCACGTAGTGCAATTGTTAATTAAACTAGTCTGCAGCAAAAAACCCCTCAG (reverse). The PCR fragment was inserted after the *sfp* gene in pMAK705 ([@b7]), and the resulting temperature‐sensitive plasmid was used for gene replacement in the chromosome of BL21(DE3).

###### 

Strain comparison for PCC, DEBS and Sfp.

  Strain pair                       Heterologous component            
  --------------------------------- --------------------------------- ------
  BAP1(pBP130/pBP144/pACYCDuet‐1)   BAP1(pBP130/pBP144/pACYC‐*sfp*)   Sfp
  YW1(pBP130/pYW7317)               BAP1(pBP130/pBP144)               PCC
  YW9(pYW1200)                      BAP1(pBP130/pBP144)               DEBS

Variation in heterologous gene dosage was accomplished by coupling strains and plasmids. Final strain pairings are presented between different heterologous components. The 'Chromosome' or 'Plasmid' heading above each individual strain indicates either chromosomal‐ or plasmid‐borne gene expression for the heterologous component; plasmid‐borne expression provides a 10‐ to 50‐fold increase in gene copy. For Sfp variation, BAP1(pBP130/pBP144) was compared with BAP1(pBP130/pBP144/pACYC‐*sfp*). The PCC and DEBS components were similarly compared. For the DEBS case, strain YW9(pYW1200/pET28) could not be used for comparison purposes because of the overlapping kanamycin‐resistance marker between strain YW9 and pET28.

To verify gene expression design, the strains used to vary heterologous gene dosage were first analysed by SDS‐PAGE. As seen in [Fig. 1](#f1){ref-type="fig"}, protein levels correlate with gene dosage design. For example, the DEBS genes are observed when expressed from the pET expression plasmids but are not observed when expressed from low copy number within the chromosome. [Figure 1](#f1){ref-type="fig"} shows the same trend for the PCC and Sfp enzyme levels. Densitometry analysis was further used to assess and confirm expression differences within the SDS‐PAGE data.

![SDS‐PAGE analysis of Sfp, PCC and DEBS through different combinations of *E. coli* strains and plasmids. The size and location of the Sfp, DEBS and PCC enzymes have been denoted by black‐filled dots within the molecular weight marker notations. The Sfp, PCC and DEBS labels above the indicated lanes represent samples exhibiting enhanced protein levels as a result of enhanced gene dosage. Culture conditions were identical to those described for 6dEB product formation ([Fig. 2](#f2){ref-type="fig"}). Post culture, cells were washed and resuspended in TE buffer. Cell densities were equalized between samples and sonication was performed with a Fisher Scientific Sonic Dismembrator Model 100 at maximum setting for a tip probe for three 10 s intervals. Lysates were then centrifuged and the whole cell lysate and soluble fractions were analysed by SDS‐PAGE. Only the soluble fraction is presented. The reagents and chemicals used in this study were purchased from Fisher Scientific and Sigma. Below the gel is a semi‐quantitative densitometry analysis of protein level differences assessed using ImageJ software version 1.40g (<http://rsb.info.nih.gov/ij/>). The analysis provides the ratio of densitometry measured band densities between respective Sfp, PCC and DEBS strain pairs (as defined in [Table 2](#t2){ref-type="table"}); *n* = 3 and numbers in parentheses are standard deviations.](mbt0002-0390-f1){#f1}

Each strain was then tested for 6dEB biosynthesis with results presented in [Fig. 2](#f2){ref-type="fig"}. The 6dEB production levels were evaluated as raw and cell‐density‐normalized final culture concentrations. Production mirrored the expression results from [Fig. 1](#f1){ref-type="fig"}. Comparing the Sfp, PCC and DEBS heterologous components indicates that between reduced and increased copy numbers, the PCC and DEBS genes had the largest impact on final biosynthesis. The impact caused by the reduction in PCC levels is in contrast to results seen previously where the PCC genes were integrated into the *ygfG* region of the *E. coli* chromosome ([@b4]). The strain reported showed no drop in 6dEB levels; whereas, our strain shows a marked reduction in 6dEB. Potential reasons for this discrepancy include the different locations for chromosomal localization and a slightly different genetic construction for the previously reported PCC where both subunit genes were under separate T7 promoters.

![Production of 6dEB as a function of the plasmids and strains varying Sfp, PCC and DEBS levels. Glycerol stocks (15%) were used to start overnight cultures (2 ml) of strain--plasmid combinations at 30°C and 250 r.p.m. in Luria--Bertani medium with antibiotic selection as appropriate \[carbenicillin (100 mg l^--1^), kanamycin (50 mg l^--1^), chloramphenicol (34 mg l^--1^)\]. The starter cultures were then used to inoculate 3 ml Luria--Bertani production cultures (at 2%, v/v) containing antibiotics (at the same concentrations referenced above), 100 µM isopropyl β‐D‐1‐thiogalactopyranoside and 20 mM sodium propionate. The production cultures were incubated at 22°C and 250 r.p.m. for 3 days, and final culture optical density (OD) was measured at 600 nm. Triplicate samples were used for each batch and three batches were conducted to ensure statistical analysis and reproducibility. After the culture period was completed, the different strains were clarified by centrifugation and the supernatant analysed for 6dEB content using one of two methods. The first method relied on an Agilent 1100 series high‐performance liquid chromatography (HPLC) coupled with an Alltech 800 series evaporative light‐scattering detector (ELSD) and has been described previously ([@b10]). The second method of 6dEB analysis relied on MS and has also been described previously ([@b11]). The MS method was reserved for those samples whose 6dEB titres were below the detection limit of the HPLC‐ELSD method. For MS analysis, erythromycin (ACROS organics) was used as an internal standard. Final *E. coli* production cultures were extracted with 1.5 ml ethyl acetate. After centrifugation at 2500 r.p.m. for 5 min, 0.75 ml of the ethyl acetate extract was dried overnight and 50 µl of methanol containing 5 mg l^--1^ erythromycin was added to re‐dissolve samples. In a similar manner, 6dEB standard samples were prepared; cultures of BAP1 were allowed to proceed for 3 days as described above before a series of 6dEB standards were added prior to the extraction with ethyl acetate and sample resuspension in methanol containing erythromycin. The samples were analysed using a LTQ XL Linear Ion Trap Mass Spectrometer (Thermo Electron Corporation) by injection through a 250 µl syringe at a speed of 10 µl min^--1^. The 6dEB standard samples were used to develop a calibration curve, and the ratio of 6dEB peak intensity to the erythromycin internal standard was correlated to sample 6dEB concentrations by using a calibration curve made before every experimental analysis. Statistical analysis was completed for each comparison pair presented in [Table 2](#t2){ref-type="table"}. While the effect on 6dEB levels was not significant for the Sfp gene dosage variation comparison, changes associated with PCC and DEBS were statistically significant (95% confidence). Below the bar graph is a final summary collected from the densitometry and 6dEB titre data of [Figs 1](#f1){ref-type="fig"} and 2; a sensitivity parameter has been defined as the ratio of high and low gene copy 6dEB titres (Fig. 2) divided by the ratio of high and low gene copy protein levels ([Fig. 1](#f1){ref-type="fig"}) for each heterologous component varied.](mbt0002-0390-f2){#f2}

Combined data from the SDS‐PAGE and 6dEB production analyses ([Fig. 2](#f2){ref-type="fig"}) suggest 6dEB biosynthesis is most significantly affected by DEBS gene and protein levels. Protein level data imply that boosting DEBS impacts 6dEB production to a larger extent when compared with PCC and Sfp. In other words, 6dEB titres show a greater response to changes in DEBS protein levels and though the combined results indicate that 6dEB production would improve by further enhancement of both PCC and DEBS protein levels, impact is expected to be greater by improving DEBS levels. In summary, the effect on *E. coli* 6dEB biosynthesis caused by heterologous component copy number variation is ranked as DEBS \> PCC \> Sfp.
